Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide Consumer Healthcare net revenue was flat at $598 mil. during the second quarter, Wyeth announces July 20. Net revenue for the division worldwide during the first six months of 2006 decreased 5% to $1.16 bil. when compared to the first six months of 2005. An increase in sales of Advil and Centrum vitamins helped offset losses caused by lower sales of Robitussin, Dimetapp and Advil Cold & Sinus, which resulted from increased retailer restrictions on pseudoephedrine-containing products, the company says. The earnings also reflect the loss of Solgar vitamin sales; the brand was divested to NBTY in the third quarter of 2005 (1"The Tan Sheet" Jan. 16, 2006, p. 13). Wyeth Nutrition's second-quarter net revenue increased 13% over the prior-year period to $300 mil...
You may also be interested in...
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.